The Asia Pacific Pen needles market size is forecasted to worth USD 0.76 billion by 2025 from USD 0.4 billion in 2020, growing at a CAGR of 14.10% from 2020 to 2025.
Growing in the preference for pen needles rather than syringes and vials, growth in geriatric populations are the key factor that drives the APAC pen needles market. Japan accounted for the largest share of the Asia-Pacific pen needles market in 2019, whereas India is estimated to grow at the highest CAGR during the forecast period.
The Chinese pen needles market is another promising region in the Asia Pacific market. Increasing diabetic patients in this region primarily drive the growth of the market in China. China is the country with the most massive diabetic patients worldwide, with around 116 million people suffering from diabetics. Overweight people are also highly susceptible to diabetes. According to the report, obesity is assumed to account for 80-85% of the risk of developing diabetes expected to drive the market growth in this region.
Indian pen needles market is predicted to grow at the highest CAGR from 2019 to 2024. The growth of the market is attributed to increasing awareness towards the availability of the latest technological devices for diabetes care, and the Indian government is also taking initiatives to spend on diabetes care and research to improve treatment techniques methods for diabetic patients. Rising market penetration by key players and the development of improved pen needle technologies. For instance, Terumo Japan-based company has launched advanced Nanopass 34G- the world's thinnest double tapered pen needles.
This research report on the Asia-Pacific Pen Needles Market has been segmented and sub-segmented into the following categories:
By Therapy:
By Type:
By Needle Length:
By Mode of Purchase:
By Country:
Companies that are dominating the APAC Pen Needles market Becton Dickinson and Company, Novo Nordisk A/S, Ypsomed Holding AG (Switzerland), UltiMed, Inc., Allison Medical, Inc., Owen Mumford, Ltd., B. Braun Melsungen, Artsana S.p.a., HTL-STREFA S.A. and Terumo Corporation (Japan).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Therapy
5.1.1 Introduction
5.1.2 Insulin Therapy
5.1.3 GLP-1 Therapy Growth Hormone Therapy
5.1.4 Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 Standard Needle
5.2.3 Safety Needle
5.3 Needle Length
5.3.1 Introduction
5.3.2 4mm
5.3.3 6mm
5.3.4 8mm
5.3.5 10mm
5.3.6 12mm
5.4 Mode of Purchase
5.4.1 Introduction
5.4.2 Retail
5.4.3 Non-Retail
6.3 Asia-Pacific
6.1 Introduction
6.2 China
6.3 India
6.4 Japan
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Becton, Dickinson and Company (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Novo Nordisk A/S (Denmark)
8.3 Ypsomed Holding AG (Switzerland)
8.4 UltiMed, Inc. (U.S.)
8.5 Allison Medical, Inc. (U.S.)
8.6 Owen Mumford, Ltd. (U.K.)
8.7 B. Braun Melsungen (Germany)
8.8 Artsana S.p.a. (Italy)
8.9 HTL-STREFA S.A. (Poland)
8.10 Terumo Corporation (Japan)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
Feb 2020
